People: Aeglea Bio Therapeutics Inc (AGLE.OQ)

AGLE.OQ on NASDAQ Stock Exchange Global Market

1:30am IST
Change (% chg)

$0.09 (+0.99%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Hebel, Henry 

Mr. Henry L. Hebel is Vice President - Product Development of the Company. He joined our company in May 2015 as Vice President, Operations and was appointed Vice President, Product Development in October 2015. Since June 2014, Mr. Hebel has served as the President of The Hebel Consulting Group. From February 2012 to June 2014, Mr. Hebel served as the Vice President of Drug Development for Terapio Corp. Additionally, Mr. Hebel was Chief Operating Officer of VGXI Inc. from April 2001 to January 2012. Prior to VGXI, Mr. Hebel served in various product development management and operations roles at Qiagen, Inc., Gene Medicine Inc., and Tanox Biosystems, Inc. Mr. Hebel holds a B.S. in Zoology and an MBA from Texas A&M University.

Basic Compensation

Total Annual Compensation, USD 380,081
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 78,961
Fiscal Year Total, USD 459,042

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --